Sugi Predict

Sugi Predict / Compounds / SCHEMBL4160100

SCHEMBL4160100

SCHEMBL4160100

C[C@H](N)C(=O)O[Si](OC(C)(C)C)(OC(C)(C)C)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 1/20 0.33
▸ GRIN3B O60391 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2A Q12879 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33
▸ GRIN3A Q8TCU5 1/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ PMP22 Q01453 1/20 0.32
▸ NLRP3 Q96P20 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162429 0.84 SLC7A5 (0.37) —
SCHEMBL4159192 0.80 SLC7A5 (0.42) —
SCHEMBL4153722 0.78 DPP4 (0.36) —
SCHEMBL4147433 0.76 — —
SCHEMBL9815891 0.72 GRIN2D (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL320243 0.70 CYP3A4 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2315016 0.70 ALDH1A1 (0.32) —
SCHEMBL8404068 0.70 SLC1A3 (0.31) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL206710 0.70 CYP3A4 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL10453588 0.70 SLC1A3 (0.31) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099307-A1 Inverse solid phase peptide synthesis with additional capping step ACTIVOTEC SPP LIMITED (GB) 2009-04-16 — — US disclosed
US-20080242836-A1 Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support UNIVERSITY OF SOUTHAMPTON (GB) 2008-10-02 — — US disclosed
WO-2006097693-A1 CONVERGENT SOLID PHASE PEPTIDE SYNTHESIS BY REACTION OF TWO FRAGMENTS BOUND TO SOLID SUPPORT UNIVERSITY OF SOUTHAMPTON (GB) 2006-09-21 — — WO disclosed
WO-2006097698-A1 INVERSE SOLID PHASE PEPTIDE SYNTHESIS WITH ADDITIONAL CAPPING STEP ACTIVOTEC SPP LIMITED (GB) 2006-09-21 — — WO disclosed
WO-1993005065-A1 PREPARATION OF PEPTIDES BY A SOLID-PHASE SYNTHESIS AND INTERMEDIATES THEREFOR PORTON DEVELOPMENTS LIMITED (GB) 1993-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099307-A1 Inverse solid phase peptide synthesis with additional capping step RNGTT, CPSF7, CPSF1 GRIN2D 2629/4885GRIN3B 2659/4885GRIN1 3805/4885
US-20080242836-A1 Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support CPSF1, CPSF7, MAX GRIN2D 3316/4885GRIN3B 2650/4885GRIN1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.